Literature DB >> 8603343

Constitutional de novo t(1;22)(p22;q11.2) and ependymoma.

J P Park1, S Chaffee, W W Noll, C H Rhodes.   

Abstract

There is a body of evidence suggesting the presence of a tumor suppressor gene on chromosome 22 which plays a role in the pathogenesis of ependymomas. We report a patient with a de novo constitutional t(1;22)(p22;q11.2) who developed a malignant ependymoma at age 5. The patient is otherwise phenotypically normal. By fluorescence in situ hybridization (FISH) analysis, the chromosome 22 breakpoint has been localized to the region between the DiGeorge locus and BCR. Since NF2 and EWS are both distal to BCR, the are presumable not involved in this rearrangement. This patient may offer a unique opportunity to identify the chromosome 22 ependymoma tumor suppressor gene by cloning the translocation breakpoint.

Entities:  

Mesh:

Year:  1996        PMID: 8603343     DOI: 10.1016/0165-4608(95)00182-4

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  4 in total

1.  A palindrome-mediated mechanism distinguishes translocations involving LCR-B of chromosome 22q11.2.

Authors:  Anthony L Gotter; Tamim H Shaikh; Marcia L Budarf; C Harker Rhodes; Beverly S Emanuel
Journal:  Hum Mol Genet       Date:  2003-11-12       Impact factor: 6.150

2.  Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization.

Authors:  Mariarita Santi; Martha Quezado; Rubin Ronchetti; Elisabeth J Rushing
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

3.  Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.

Authors:  C Ebert; M von Haken; B Meyer-Puttlitz; O D Wiestler; G Reifenberger; T Pietsch; A von Deimling
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2.

Authors:  T J Hulsebos; N T Oskam; E H Bijleveld; A Westerveld; M A Hermsen; A M van den Ouweland; B C Hamel; C C Tijssen
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.